Aligos Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Aligos Therapeutics
ALGS Stock  USD 8.46  0.46  5.75%   
Aligos Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Aligos Therapeutics' valuation are provided below:
Gross Profit
-65.8 M
Market Capitalization
49.3 M
Enterprise Value Revenue
0.3833
Revenue
2.6 M
Earnings Share
(13.54)
There are over one hundred nineteen available fundamental signals for Aligos Therapeutics, which can be analyzed over time and compared to other ratios. All traders should validate Aligos Therapeutics' prevailing fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 272.7 M in 2026. Enterprise Value is likely to drop to about 241.4 M in 2026

Aligos Therapeutics Total Revenue

4.27 Million

Check Aligos Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aligos Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 254.7 K, Net Interest Income of 5.3 M or Interest Income of 1 M, as well as many indicators such as Price To Sales Ratio of 69.12, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Aligos financial statements analysis is a perfect complement when working with Aligos Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Aligos Stock
Check out the analysis of Aligos Therapeutics Correlation against competitors.
For more information on how to buy Aligos Stock please use our How to Invest in Aligos Therapeutics guide.

Aligos Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets59.9 M63.1 M124 M
Very volatile
Short and Long Term Debt Total10 M7.5 M12.7 M
Slightly volatile
Other Current Liabilities15.9 M17.9 M9.5 M
Slightly volatile
Total Current Liabilities26.6 M25 M16.5 M
Slightly volatile
Other Liabilities199.2 K209.7 K1 M
Pretty Stable
Property Plant And Equipment Net10.4 M6.6 M13.5 M
Slightly volatile
Current Deferred Revenue129.1 K135.9 K3.6 M
Pretty Stable
Accounts Payable2.6 M2.3 M3 M
Very volatile
Cash40.4 M42.5 M60.6 M
Slightly volatile
Non Current Assets Total13.6 M7.2 M15.5 M
Pretty Stable
Non Currrent Assets Other549.2 K721 K364.1 K
Slightly volatile
Cash And Short Term Investments48.7 M51.2 M105.2 M
Very volatile
Common Stock Shares Outstanding5.4 M5.6 M21.8 M
Pretty Stable
Liabilities And Stockholders Equity59.9 M63.1 M124 M
Very volatile
Non Current Liabilities Total52.9 M71.2 M88.1 M
Slightly volatile
Capital Lease Obligations10 M7.5 M12.7 M
Slightly volatile
Other Current Assets6.7 M6 M4 M
Slightly volatile
Other Stockholder Equity401.3 M676.9 M213.7 M
Slightly volatile
Total Liabilities72 M89.2 M103.7 M
Slightly volatile
Property Plant And Equipment Gross20.5 M22 M17.3 M
Slightly volatile
Total Current Assets53.1 M55.9 M108.9 M
Very volatile
Net Working Capital34.5 M36.4 M93.2 M
Very volatile
Short Term Debt3 M4 M2.1 M
Slightly volatile
Common Stock5.3 K9.2 K4.3 K
Slightly volatile
Property Plant Equipment4.1 M4.3 M12.1 M
Slightly volatile
Common Stock Total Equity3.2 K3.6 K3.9 K
Slightly volatile
Capital Surpluse507.8 M578 M436.8 M
Slightly volatile
Non Current Liabilities Other39.3 K41.4 K1.5 M
Pretty Stable

Aligos Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income1 M1.4 M581.8 K
Slightly volatile
Depreciation And Amortization3.2 M3 M2.2 M
Slightly volatile
Selling General Administrative21.9 M26.3 M12.6 M
Slightly volatile
Other Operating Expenses95.3 M107.1 M54 M
Slightly volatile
Research Development73.4 M80.8 M41.5 M
Slightly volatile
Cost Of Revenue2.9 M3 M8 M
Pretty Stable
Total Operating Expenses95.3 M107.1 M54 M
Slightly volatile
Reconciled Depreciation3.2 M3 M2.2 M
Slightly volatile
Selling And Marketing Expenses3 M3.4 M3.7 M
Slightly volatile

Aligos Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation8.4 M9.7 M4.3 M
Slightly volatile
Other Cashflows From Financing Activities374.5 K394.2 K61.7 M
Slightly volatile
Depreciation3.2 M3 M2.2 M
Slightly volatile
Capital Expenditures111.2 K117 K1.7 M
Slightly volatile
Total Cash From Financing Activities303.5 K319.5 K79.1 M
Slightly volatile
End Period Cash Flow40.5 M42.7 M61 M
Slightly volatile
Sale Purchase Of Stock192.4 K202.5 K106.3 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio69.1272.761.9 K
Slightly volatile
Stock Based Compensation To Revenue1.962.462.6753
Slightly volatile
Capex To Depreciation0.05420.0571.1784
Slightly volatile
EV To Sales61.1964.411.9 K
Slightly volatile
Payables Turnover0.540.90.6454
Slightly volatile
Sales General And Administrative To Revenue4.466.665.8418
Slightly volatile
Research And Ddevelopement To Revenue14.4420.4820.6046
Slightly volatile
Capex To Revenue0.0360.03790.1548
Slightly volatile
Cash Per Share4.468.185.0606
Slightly volatile
Days Payables Outstanding661418651
Slightly volatile
Income Quality0.60.550.5812
Slightly volatile
Net Debt To EBITDA0.360.380.8902
Very volatile
Current Ratio3.123.298.9655
Slightly volatile
Capex Per Share0.02270.02390.0806
Slightly volatile
Revenue Per Share0.340.570.2237
Slightly volatile
Interest Debt Per Share1.261.20.714
Slightly volatile
Debt To Assets0.09670.140.1107
Slightly volatile
Days Of Payables Outstanding661418651
Slightly volatile
Ebt Per Ebit0.861.321.0511
Slightly volatile
Quick Ratio3.123.298.9655
Slightly volatile
Net Income Per E B T0.80.90.9842
Slightly volatile
Cash Ratio1.861.963.5087
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.181.151.246
Slightly volatile
Fixed Asset Turnover0.70.480.4651
Slightly volatile
Debt Ratio0.09670.140.1107
Slightly volatile
Price Sales Ratio69.1272.761.9 K
Slightly volatile
Asset Turnover0.05440.05070.0342
Slightly volatile

Aligos Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap272.7 M287 M7.8 B
Slightly volatile
Enterprise Value241.4 M254.1 M7.7 B
Slightly volatile

Aligos Fundamental Market Drivers

Aligos Upcoming Events

14th of March 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Aligos Therapeutics Financial Statements

Aligos Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Aligos Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Aligos Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Aligos Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue135.9 K129.1 K
Total Revenue4.5 M4.3 M
Cost Of Revenue3 M2.9 M
Stock Based Compensation To Revenue 2.46  1.96 
Sales General And Administrative To Revenue 6.66  4.46 
Research And Ddevelopement To Revenue 20.48  14.44 
Capex To Revenue 0.04  0.04 
Revenue Per Share 0.57  0.34 
Ebit Per Revenue(20.34)(21.36)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Aligos Stock Analysis

When running Aligos Therapeutics' price analysis, check to measure Aligos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aligos Therapeutics is operating at the current time. Most of Aligos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aligos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aligos Therapeutics' price. Additionally, you may evaluate how the addition of Aligos Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY